---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-23-003210"
form_type: "8-K"
ticker: "SBFM"
cik: "0001402328"
company_name: "Sunshine Biopharma Inc."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T03:52:12.605760+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Sunshine Biopharma reports Q1 2023 revenues of $4.89M, up 2,100% YoY

## Summary
- Gross revenues of $4,894,053 for Q1 2023, a 2,100% increase over Q1 2022, driven by Nora Pharma acquisition.
- Repurchased 445,711 common shares under $2M stock buyback program; shares cancelled, reducing outstanding count to 22,139,921.
- Entered research agreement with Jewish General Hospital to advance Adva-27a anticancer compound through IND-enabling studies.
- Obtained exclusive worldwide license from University of Arizona for PLpro protease inhibitors of SARS-CoV-2 (COVID-19).

## SEC filing metadata
- accession: 0001683168-23-003210
- form_type: 8-K
- ticker: SBFM
- cik: 0001402328
- company_name: Sunshine Biopharma Inc.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1402328/000168316823003210/0001683168-23-003210-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1402328/000168316823003210/sunshine_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-23-003210
- JSON: https://secwatch.observer/filing/0001683168-23-003210.json
- Plain text: https://secwatch.observer/filing/0001683168-23-003210.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.